The molecular and clinical rationale of extracorporeal photochemotherapy in autoimmune diseases, malignancies and transplantation
- PMID: 20044039
- DOI: 10.1016/j.autrev.2009.12.011
The molecular and clinical rationale of extracorporeal photochemotherapy in autoimmune diseases, malignancies and transplantation
Abstract
Extracorporeal photochemotherapy, or photopheresis is a low-risk therapeutical intervention, which has been introduced in a variety of hematological malignancies, autoimmune conditions and transplantation. The mode of action of photopheresis encompasses apoptosis-induction and modifications of immunoregulatory processes, leading to the elimination of malignant cells, as well as the down-modulation of harmful immune responses. Although the beneficial effects of the therapy have been depicted in numerous studies, little is known about the exact benefits and the molecular mechanisms behind. The aim of the present review was to portray some aspects of the molecular and clinical rationale of extracorporeal photochemotherapy in autoimmune diseases, malignancies and transplantation, and to provide an overview of the treatment in the modern clinical management of these diseases.
Copyright 2009 Elsevier B.V. All rights reserved.
Similar articles
-
Extracorporeal photochemotherapy.J Dermatol Sci. 2009 Jun;54(3):150-6. doi: 10.1016/j.jdermsci.2009.03.002. Epub 2009 Apr 14. J Dermatol Sci. 2009. PMID: 19369039 Review.
-
Extracorporeal photopheresis: from solid organs to face transplantation.Transpl Immunol. 2009 Jul;21(3):117-28. doi: 10.1016/j.trim.2009.04.005. Epub 2009 May 3. Transpl Immunol. 2009. PMID: 19409991 Review.
-
Updating ECP action mechanisms.Transfus Apher Sci. 2014 Jun;50(3):330-9. doi: 10.1016/j.transci.2014.04.003. Epub 2014 Apr 13. Transfus Apher Sci. 2014. PMID: 24837416 Review.
-
[Extracorporeal photochemotherapy].Transfus Clin Biol. 2010 Feb;17(1):28-33. doi: 10.1016/j.tracli.2009.10.005. Epub 2009 Dec 29. Transfus Clin Biol. 2010. PMID: 20042357 Review. French.
-
Uptake of donor lymphocytes treated with 8-methoxypsoralen and ultraviolet A light by recipient dendritic cells induces CD4+CD25+Foxp3+ regulatory T cells and down-regulates cardiac allograft rejection.Biochem Biophys Res Commun. 2010 May 14;395(4):540-6. doi: 10.1016/j.bbrc.2010.04.062. Epub 2010 Apr 13. Biochem Biophys Res Commun. 2010. PMID: 20394727
Cited by
-
Emerging trends for radioimmunotherapy in solid tumors.Cancer Biother Radiopharm. 2013 Nov;28(9):639-50. doi: 10.1089/cbr.2013.1523. Epub 2013 Jul 11. Cancer Biother Radiopharm. 2013. PMID: 23844555 Free PMC article. Review.
-
The effects of extracorporeal photochemotherapy on T cell activation and regulatory mechanisms in patients with systemic sclerosis.Clin Rheumatol. 2012 Sep;31(9):1293-9. doi: 10.1007/s10067-012-2000-x. Epub 2012 Jun 16. Clin Rheumatol. 2012. PMID: 22706443
-
Application of Photodynamic Therapy with 5-Aminolevulinic Acid to Extracorporeal Photopheresis in the Treatment of Patients with Chronic Graft-versus-Host Disease: A First-in-Human Study.Pharmaceutics. 2021 Sep 26;13(10):1558. doi: 10.3390/pharmaceutics13101558. Pharmaceutics. 2021. PMID: 34683851 Free PMC article.
-
Sensitive Photodynamic Detection of Adult T-cell Leukemia/Lymphoma and Specific Leukemic Cell Death Induced by Photodynamic Therapy: Current Status in Hematopoietic Malignancies.Cancers (Basel). 2020 Feb 2;12(2):335. doi: 10.3390/cancers12020335. Cancers (Basel). 2020. PMID: 32024297 Free PMC article. Review.
-
The assessment of immune-regulatory effects of extracorporeal photopheresis in systemic sclerosis: a long-term follow-up study.Immunol Res. 2016 Apr;64(2):404-11. doi: 10.1007/s12026-015-8678-5. Immunol Res. 2016. PMID: 26168768
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical